Figure 2.

Effects of rosiglitazone (Rosi) or CMHX008 (CMHX) on body weight (BW), food intake (FI), glucose homeostasis, and metabolic rate. (A) BW of HFD and LFD mice treated with 10 mg/kg/day of Rosi or CMHX for 16 weeks (n = 10–13/group). (B) BW changes in ob/ob mice treated with 10 mg/kg/day of Rosi or CMHX for 16 weeks (n = 4–6/group). (C) Daily FI of mice treated with 10 mg/kg/day measured two weeks before sacrifice (n = 4–6/group). (D) Glucose tolerance test (GTT) of HFD mice treated with 10 mg/kg/day performed at 10 weeks after treatment with the chemicals and area under the curve (AUC) of GTT (n = 5–10/group). (E) BW of HFD mice treated with 3 mg/kg/day of Rosi or CMHX for 16 weeks (n = 5/group). (F) GTT of HFD mice treated with 3 mg/kg/day performed at 10 weeks after treatment with the chemicals and AUC of GTT (n = 7/group). (G–I) Oxygen consumption (VO₂), carbon dioxide production (VCO₂) and ambulatory activity were measured for HFD mice treated with 10 mg/kg/day. *P < 0.05, **P < 0.01, versus Veh, ^#P < 0.05, ^##P < 0.01 versus Rosi.